Novartis finalizes divestment of ‘front of eye’ ophthalmology assets
September 30th 2023According to the company, the divestment includes Xiidra, on-market treatment for dry eye disease and additional ophthalmic investigational therapies. Novartis will now move forward with a focused portfolio and prioritized therapeutic areas for future growth.
Outlook Therapeutics requests Type A meeting with FDA
September 29th 2023According to Outlook, in the FDA’s recently issued CRL it concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.
Thea Pharma rolls out latanoprost ophthalmic solution 0.005% in the US
September 27th 2023Preservative-free Iyuzeh, launched more than 10 years ago, currently is available in 46 countries, mostly under the brand name Monoprost, with about 1.5 million patients treated monthly, according to the company.
EyePod: Transforming the MIGS pipeline into clinical reality
September 26th 2023Peter J. McDonnell, MD, and Neda Shamie, MD, discuss the transformative impact of minimally invasive glaucoma surgery (MIGS) on glaucoma care and its integration with cataract surgery, sharing insights and practical tips for ophthalmologists.
Eyecbetter announces Amy Dixon, PLY (Paralympian), as new Director of Patient Advocacy
September 23rd 2023As a gold medalist with profound vision loss, she will lead advocacy efforts for people with glaucoma that are designed to empower patients to participate actively in their glaucoma treatment journey